This website is for UK healthcare professionals and UK healthcare decision makers only

Reporting adverse events
A
A
Prescribing information for:

Ferinject 
(ferric carboxymaltose)

Kapruvia ▼
(difelikefalin)

Tavneos ▼
(avacopan)

Veltassa 
(patiromer)

Venofer 
(iron sucrose)

Key information on Veltassa (patiromer), including efficacy and
tolerability data, how to prescribe and patients who
may benefit from treatment

FERINJECT®
(ferric carboxymaltose)

KAPRUVIA®(difelikefalin)

TAVNEOS®(avacopan)

VELTASSA®
(patiromer)

WEBINARS
AND EVENTS

Veltassa efficacy

Learn more about short-term and long-term K+ control with Veltassa

Veltassa and RAASi

Discover the key clinical trials that show how Veltassa could enable RAASi therapy through the control of elevated K+

Veltassa tolerability

Find out more about Veltassa’s mode of action and tolerability profile

Once daily dosing

Understand how patients should prepare Veltassa and learn about the once-daily dosing regime

Transfer of care

Learn more about how patients can be initiated on Veltassa in secondary care and continued in primary care

Chronic Patient case studies

Review two patient case studies where persistent elevated K+ is preventing optimal RAAS inhibition therapy and decide whether Veltassa could help

Acute patient case study

Review a patient with acute hyperkalaemia and understand where Veltassa could fit within their treatment

VELTASSA IN THE ACUTE SETTING

See how daily doses of Veltassa as a monotherapy provided potassium control to patients in a cohort study of hyperkalaemia in the acute care setting.

 

 

RAAS, renin-angiotensin-aldosterone system ; RAASi, renin-angiotensin-aldosterone system inhibition.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma UK Ltd. (Tel 01276 853633). Email: medicalinfo_UK@viforpharma.com
More Resources

Ferinject

Resources

Webinars and events

Resources

You are now heading to a third-party website that we do
not operate. We are not responsible for the content of the
third-party website. You are advised to review its privacy policy
as it may differ from ours.

 

Are you sure you want to leave?

Confirm

Cancel

Report adverse events in the UK:

Adverse events should be reported. Reporting forms and information for United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma Ltd. Tel: +44 1276 853633. E-mail: medicalInfo_UK@viforpharma.com